Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7597149 | 0.94 | POLB (0.48) | POLBP2RX4ASAH1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7645474 | 0.77 | APEX1 (0.48) | POLBP2RX4ASAH1SMN1; SMN2APEX1 | |
| SCHEMBL15773010 | 0.67 | GAA (0.50) | ASAH1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL3300277 | 0.65 | ALDH1A1 (0.49) | POLBALDH1A1SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL176484 | 0.65 | TSHR (0.53) | POLBALDH1A1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3301756 | 0.65 | TMEM97 (0.51) | ALDH1A1CYP1A2APEX1MEN1KMT2A | |
| SCHEMBL2267441 | 0.65 | KDM4E (0.47) | POLBALDH1A1SMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2531923 | 0.64 | GAA (0.53) | POLBALDH1A1SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL7058470 | 0.64 | GSK3A (0.46) | ALDH1A1APEX1KDM4EKMT2ASLC6A2 | |
| SCHEMBL8947389 | 0.64 | HTR4 (0.41) | ALDH1A1HPGDLMNAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | POLB 3257/4885P2RX4 3469/4885ASAH1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.